Table 1:

Adjustment factors for biologic prices

BiologicPrimary analysis: adjustment factor, %Policy consideration #1: include insulin glargine, %Policy consideration #2: include biosimilar for adalimumab, %Policy consideration #3: negotiated price reductions below threshold, %
Etanercept62.062.862.875, 50
Infliximab53.253.253.275, 50
AdalimumabNANA60.075, 50
Insulin glargineNA75.0NANA
  • Note: NA = not applicable.